Literature DB >> 20308377

Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.

Kai Lin1, Sylwia Karwowska, Eric Lam, Kay Limoli, Thomas G Evans, Claudio Avila.   

Abstract

Most approved drugs with activity against hepatitis B virus (HBV) have activity against human immunodeficiency virus type 1 (HIV-1), which precludes their use in patients who are coinfected with HBV and HIV-1 and who are not receiving antiretroviral therapy due to the risk of inducing resistance. The activity of telbivudine, a highly selective HBV inhibitor, against temporally and geographically distinct wild-type and multidrug-resistant HIV-1 clinical isolates was evaluated in vitro. No inhibition was observed with up to 600 muM drug, which supports further exploration of telbivudine as a therapeutic option for the treatment of HBV infections in patients coinfected with HIV-1.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308377      PMCID： PMC2876362          DOI： 10.1128/AAC.01703-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Telbivudine has activity against HIV-1.

Authors:  Emma Low; Alison Cox; Mark Atkins; Mark Nelson
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

2.  Antiviral beta-L-nucleosides specific for hepatitis B virus infection.

Authors:  D N Standring; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; E Cretton-Scott; R F Schinazi; M Myers; M L Bryant; J P Sommadossi
Journal:  Antivir Chem Chemother       Date:  2001

3.  Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.

Authors:  Robert G Gish; Huy Trinh; Nancy Leung; Francis K L Chan; Michael W Fried; Teresa L Wright; Chia Wang; Jane Anderson; Elsa Mondou; Andrea Snow; Jeff Sorbel; Franck Rousseau; Lawrence Corey
Journal:  J Hepatol       Date:  2005-04-11       Impact factor: 25.083

4.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.

Authors:  G J Dore; D A Cooper; C Barrett; L E Goh; B Thakrar; M Atkins
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort.

Authors:  L M M Wolters; H G M Niesters; B E Hansen; M E van der Ende; F P Kroon; C Richter; K Brinkman; P L Meenhorst; R A de Man
Journal:  J Clin Virol       Date:  2002-04       Impact factor: 3.168

7.  Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.

Authors:  Julie A Sheldon; Angélica Corral; Berta Rodés; Stefan Mauss; Juergen Rockstroh; Florian Berger; Carolynne Schwarze-Zander; Vincent Soriano
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

Review 8.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

Authors:  Vincent Soriano; Massimo Puoti; Marion Peters; Yves Benhamou; Mark Sulkowski; Fabien Zoulim; Stefan Mauss; Juergen Rockstroh
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

9.  Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.

Authors:  Laura Milazzo; Ilaria Caramma; Alessia Lai; Michela Violin; Chiara De Maddalena; Miriam Cesari; Massimo Galli; Claudia Balotta
Journal:  Antivir Ther       Date:  2009

10.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Authors:  Gregory J Dore; David A Cooper; Anton L Pozniak; Edwin DeJesus; Lijie Zhong; Michael D Miller; Biao Lu; Andrew K Cheng
Journal:  J Infect Dis       Date:  2004-03-12       Impact factor: 5.226
View more
  5 in total

1.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 2.  Telbivudine: a review of its use in compensated chronic hepatitis B.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

3.  Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

Authors:  Noortje M van Maarseveen; Annemarie Mj Wensing; Dorien de Jong; Greg L Beilhartz; Aleksandr Obikhod; Sijia Tao; Marieke Pingen; Joop E Arends; Andy Im Hoepelman; Raymond F Schinazi; Matthias Götte; Monique Nijhuis
Journal:  Antivir Ther       Date:  2011

Review 4.  Review of hepatitis B therapeutics.

Authors:  Debika Bhattacharya; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2010-10-18       Impact factor: 9.079

5.  Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.

Authors:  Ann E Cleves; Ajay N Jain
Journal:  J Comput Aided Mol Des       Date:  2014-11-27       Impact factor: 3.686
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.